@newsen.bsky.socialOct 6, 2026, 5:00 AMAnnJi Pharmaceutical Advances Pivotal Phase 3 Study for AJ201 Targeting Spinal and Bulbar Muscular Atrophy #Taipei #USA #AJ201 #SBMA #AnnJi
@newsen.bsky.socialOct 5, 2026, 4:40 AMAnnJi Pharmaceutical Takes Significant Step with AJ201 in Phase 3 Trial for SBMA #None #AJ201 #SBMA #AnnJi
@newsen.bsky.social@newsen.bsky.social@newsen.bsky.social